Janus Henderson Group PLC Takes $23.44 Million Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)

Janus Henderson Group PLC bought a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,046,899 shares of the company's stock, valued at approximately $23,435,000. Janus Henderson Group PLC owned approximately 17.16% of Monopar Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in MNPR. RA Capital Management L.P. acquired a new position in shares of Monopar Therapeutics during the 4th quarter valued at $11,247,000. Adage Capital Partners GP L.L.C. bought a new position in Monopar Therapeutics during the fourth quarter valued at about $13,182,000. ADAR1 Capital Management LLC bought a new position in Monopar Therapeutics during the fourth quarter valued at about $2,861,000. Geode Capital Management LLC grew its holdings in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after acquiring an additional 24,530 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics in the fourth quarter worth about $45,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the company's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the transaction, the insider now owns 822,255 shares in the company, valued at $28,778,925. This represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on MNPR shares. Piper Sandler restated an "overweight" rating and set a $76.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Finally, Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd.

Monopar Therapeutics Stock Up 0.3%

Shares of NASDAQ MNPR traded up $0.12 during mid-day trading on Wednesday, hitting $37.02. 2,434 shares of the company traded hands, compared to its average volume of 357,972. Monopar Therapeutics Inc. has a 1 year low of $1.72 and a 1 year high of $54.30. The stock has a market capitalization of $226.35 million, a price-to-earnings ratio of -18.79 and a beta of 1.11. The business has a 50 day moving average of $37.77 and a two-hundred day moving average of $32.06.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.27. As a group, research analysts anticipate that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Monopar Therapeutics Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.